STOCK TITAN

Moderna (MRNA) Chief Commercial Officer awarded RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. reported that Chief Commercial Officer Banque Soria Ester received new equity awards as part of compensation. She was granted 38,364 restricted stock units, each convertible into one share of common stock. She was also granted 18,658 stock options with an exercise price of $79.76 per share.

For both awards, 25% are scheduled to vest on July 5, 2027, with the remaining portions vesting in twelve equal quarterly installments after that date. These are awards from the company and do not involve any open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Banque Soria Ester
Role Chief Commercial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 18,658 $0.00 --
Grant/Award Restricted Stock Units 38,364 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 18,658 shares (Direct); Restricted Stock Units — 38,364 shares (Direct)
Footnotes (1)
  1. 25% of this option will vest and become exercisable on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Restricted stock units convert into common stock on a one-for-one basis. 25% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
RSU grant size 38,364 units Restricted stock units granted to CCO, one-for-one into common stock
Stock option grant size 18,658 options New stock options granted to CCO
Option exercise price $79.76 per share Conversion or exercise price for stock options
RSU vesting start July 5, 2027 25% of RSU award vests on this date
Option vesting start July 5, 2027 25% of options vest and become exercisable on this date
Remaining vesting pattern 12 quarterly installments Remaining 75% of both RSUs and options vest quarterly
Option expiration July 5, 2036 Expiration date of the granted stock options
Restricted Stock Units financial
"security_title: Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 79.7600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"25% of this option will vest and become exercisable on July 5, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
quarterly installments financial
"remainder vesting in twelve (12) equal quarterly installments thereafter"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Moderna (MRNA) grant to its Chief Commercial Officer?

Moderna granted its Chief Commercial Officer 38,364 restricted stock units and 18,658 stock options. The options have an exercise price of $79.76 per share, and both awards follow a multi-year vesting schedule beginning in July 2027.

What is the vesting schedule for the new Moderna (MRNA) equity awards?

Both the RSUs and options vest with 25% on July 5, 2027. The remaining 75% of each award then vests in twelve equal quarterly installments, spreading vesting over several years to encourage longer-term retention.

What is the exercise price of the new Moderna (MRNA) stock options?

The newly granted stock options have an exercise price of $79.76 per share. This means the executive can buy Moderna common stock at $79.76 per share once the options vest and are exercisable, subject to the award’s terms.

Did the Moderna (MRNA) Chief Commercial Officer buy or sell shares in the market?

No open-market purchases or sales are reported in this filing. The Form 4 shows grant/award acquisitions of RSUs and stock options only, which are compensation awards rather than discretionary market trades in Moderna shares.

How many Moderna (MRNA) restricted stock units now belong to the Chief Commercial Officer?

After this transaction, the Chief Commercial Officer holds 38,364 restricted stock units. Each unit represents the right to receive one share of Moderna common stock when it vests and settles, following the defined vesting schedule.

When do the newly granted Moderna (MRNA) stock options expire?

The newly granted stock options are scheduled to expire on July 5, 2036. The options vest over time starting in 2027, and any unexercised options would lapse after the stated expiration date if not exercised earlier.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Banque Soria Ester

(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$79.7607/05/2026A18,658 (1)07/05/2036Common Stock18,658$018,658D
Restricted Stock Units(2)07/05/2026A38,364 (3) (3)Common Stock38,364$038,364D
Explanation of Responses:
1. 25% of this option will vest and become exercisable on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
2. Restricted stock units convert into common stock on a one-for-one basis.
3. 25% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ James Dillon, as Attorney-in-Fact07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)